The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.
Adaptive designs for confirmatory clinical trials
Abstract
Adaptive designs play an increasingly important role in clinical drug development. Such designs use accumulating data of an ongoing trial to decide how to modify design aspects without undermining the validity and integrity of the trial. Adaptive designs thus allow for a number of possible adaptations at midterm: Early stopping either for futility or success, sample size reassessment, change of population, etc. A particularly appealing application is the use of adaptive designs in combined phase II/III studies with treatment selection at interim. The expectation has arisen that carefully planned and conducted studies based on adaptive designs increase the efficiency of the drug development process by making better use of the observed data, thus leading to a higher information value per patient. In this paper we focus on adaptive designs for confirmatory clinical trials. We review the adaptive design methodology for a single null hypothesis and how to perform adaptive designs with multiple hypotheses using closed test procedures. We report the results of an extensive simulation study to evaluate the operational characteristics of the various methods. A case study and related numerical examples are used to illustrate the key results. In addition we provide a detailed discussion of current methods to calculate point estimates and confidence intervals for relevant parameters. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
Dunnett, C. W. (1955) · Journal of the American Statistical Association · doi:10.1080/01621459.1955.10501294 · Cited by 6,094
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
An improved Bonferroni procedure for multiple tests of significance
SIMES, R. J. (1986) · Biometrika · doi:10.1093/biomet/73.3.751 · Cited by 2,396
Multiple Comparison Procedures
Hochberg, Y., & Tamhane, A. C. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316672 · Cited by 2,389
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Evaluation of Experiments with Adaptive Interim Analyses
Bauer, P., & Kohne, K. (1994) · Biometrics · doi:10.2307/2533441 · Cited by 865
Bayesian approaches to randomized trials
Spiegelhalter, D. J., Freedman, L. S., & Parmar, M. K. B. (1994) · Journal of the Royal Statistical Society. Series A (Statistics in Society) · doi:10.2307/2983527 · Cited by 720
Group Sequential Methods with Applications to Clinical Trials
Kim, K. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00127-6 · Cited by 706
Adaptive Sample Size Calculations in Group Sequential Trials
Lehmacher, W., & Wassmer, G. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.01286.x · Cited by 598
Modification of Sample Size in Group Sequential Clinical Trials
Cui, L., Hung, H. M. J., & Wang, S. (1999) · Biometrics · doi:10.1111/j.0006-341x.1999.00853.x · Cited by 574
Designed Extension of Studies Based on Conditional Power
Proschan, M. A., & Hunsberger, S. A. (1995) · Biometrics · doi:10.2307/2533262 · Cited by 534
Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
Bretz, F., Pinheiro, J. C., & Branson, M. (2005) · Biometrics · doi:10.1111/j.1541-0420.2005.00344.x · Cited by 398
Self-citationMüller, H.-H., & Schäfer, H. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00886.x · Cited by 372
Adaptive Designs in Clinical Drug Development—An Executive Summary of the PhRMA Working Group
Gallo, P., Chuang-Stein, C., Dragalin, V., Gaydos, B., Krams, M., & Pinheiro, J. (2006) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400600614742 · Cited by 323
Combining different phases in the development of medical treatments within a single trial
Bauer, P., & Kieser, M. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990730)18:14<1833::aid-sim221>3.0.co;2-3 · Cited by 287
Bretz, F., Schmidli, H., König, F., Racine, A., & Maurer, W. (2006) · Biometrical Journal · doi:10.1002/bimj.200510232 · Cited by 272
Self-citationApproaches to evaluation of treatment effect in randomized clinical trials with genomic subset
Wang, S., O'Neill, R. T., & Hung, H. M. J. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.300 · Cited by 263
On the bias of maximum likelihood estimation following a sequential test
WHITEHEAD, J. (1986) · Biometrika · doi:10.1093/biomet/73.3.573 · Cited by 247
Testing and estimation in flexible group sequential designs with adaptive treatment selection
Posch, M., Koenig, F., Branson, M., Brannath, W., Dunger‐Baldauf, C., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2389 · Cited by 243
Self-citationBrannath, W., Posch, M., & Bauer, P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479374 · Cited by 240
Self-citationParameter estimation following group sequential hypothesis testing
EMERSON, S. S., & FLEMING, T. R. (1990) · Biometrika · doi:10.1093/biomet/77.4.875 · Cited by 224
Exact Confidence Intervals Following a Group Sequential Test
Tsiatis, A. A., Rosner, G. L., & Mehta, C. R. (1984) · Biometrics · doi:10.2307/2530924 · Cited by 224
Sequential designs for phase III clinical trials incorporating treatment selection
Stallard, N., & Todd, S. (2003) · Statistics in Medicine · doi:10.1002/sim.1362 · Cited by 203
Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology
Brannath, W., Zuber, E., Branson, M., Bretz, F., Gallo, P., Posch, M., & Racine‐Poon, A. (2009) · Statistics in Medicine · doi:10.1002/sim.3559 · Cited by 200
Self-citationInnovative Approaches for Designing and Analyzing Adaptive Dose-Ranging Trials
Bornkamp, B., Bretz, F., Dmitrienko, A., Enas, G., Gaydos, B., Hsu, C.-H., König, F., Krams, M., Liu, Q., Neuenschwander, B., et al. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701643848 · Cited by 195
Self-citationThall, P. F., Simon, R., & Ellenberg, S. S. (1989) · Biometrics · doi:10.2307/2531495 · Cited by 185
Mid‐course sample size modification in clinical trials based on the observed treatment effect
Jennison, C., & Turnbull, B. W. (2003) · Statistics in Medicine · doi:10.1002/sim.1457 · Cited by 180
Adaptive Modifications of Hypotheses After an Interim Analysis
Hommel, G. (2001) · Biometrical Journal · doi:10.1002/1521-4036(200109)43:5<581::aid-bimj581>3.0.co;2-j · Cited by 170
A general statistical principle for changing a design any time during the course of a trial
Müller, H., & Schäfer, H. (2004) · Statistics in Medicine · doi:10.1002/sim.1852 · Cited by 152
Repeated confidence intervals for group sequential clinical trials
Jennison, C., & Turnbull, B. W. (1984) · Controlled Clinical Trials · doi:10.1016/0197-2456(84)90148-x · Cited by 150
Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples
Maca, J., Bhattacharya, S., Dragalin, V., Gallo, P. P., & Krams, M. (2006) · Drug Information Journal · doi:10.1177/216847900604000412 · Cited by 143
Seamlessly Expanding a Randomized Phase II Trial to Phase III
Inoue, L. Y. T., Thall, P. F., & Berry, D. A. (2002) · Biometrics · doi:10.1111/j.0006-341x.2002.00823.x · Cited by 134
Adaptive Dunnett tests for treatment selection
König, F., Brannath, W., Bretz, F., & Posch, M. (2007) · Statistics in Medicine · doi:10.1002/sim.3048 · Cited by 130
Self-citationBayesian predictive approach to interim monitoring in clinical trials
Dmitrienko, A. A., & Wang, M. (2005) · Statistics in Medicine · doi:10.1002/sim.2204 · Cited by 127
Schmidli, H., Bretz, F., Racine, A., & Maurer, W. (2006) · Biometrical Journal · doi:10.1002/bimj.200510231 · Cited by 127
Self-citationA Unified Theory of Two-Stage Adaptive Designs
Liu, Q., Proschan, M. A., & Pledger, G. W. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502388618852 · Cited by 126
Simple procedures for blinded sample size adjustment that do not affect the type I error rate
Kieser, M., & Friede, T. (2003) · Statistics in Medicine · doi:10.1002/sim.1585 · Cited by 126
Monitoring Pairwise Comparisons in Multi-Armed Clinical Trials
Follmann, D. A., Proschan, M. A., & Geller, N. L. (1994) · Biometrics · doi:10.2307/2533376 · Cited by 122
Adaptive Bayesian Designs for Dose-Ranging Drug Trials
Berry, D. A., Müller, P., Grieve, A. P., Smith, M. K., Parke, T., Blazek, R., Mitchard, N., & Krams, M. (2002) · Lecture notes in statistics · doi:10.1007/978-1-4613-0035-9_2 · Cited by 116
A group‐sequential design for clinical trials with treatment selection
Stallard, N., & Friede, T. (2008) · Statistics in Medicine · doi:10.1002/sim.3436 · Cited by 115
Power and sample size when multiple endpoints are considered
Senn, S. J., & Bretz, F. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.301 · Cited by 111
Self-citationThe reassessment of trial perspectives from interim data—a critical view
Bauer, P., & König, F. (2005) · Statistics in Medicine · doi:10.1002/sim.2180 · Cited by 110
Issues in designing flexible trials
Posch, M., Bauer, P., & Brannath, W. (2003) · Statistics in Medicine · doi:10.1002/sim.1455 · Cited by 108
Self-citationSample Size Reestimation: A Review and Recommendations
Chuang‐Stein, C., Anderson, K. M., Gallo, P. P., & Collins, S. H. (2006) · Drug Information Journal · doi:10.1177/216847900604000413 · Cited by 107
Drop-the-Losers Design: Normal Case
Sampson, A. R., & Sill, M. W. (2005) · Biometrical Journal · doi:10.1002/bimj.200410119 · Cited by 104
Burman, C., & Sonesson, C. (2006) · Biometrics · doi:10.1111/j.1541-0420.2006.00626.x · Cited by 93
Unbiased estimation following a group sequential test
Liu, A. (1999) · Biometrika · doi:10.1093/biomet/86.1.71 · Cited by 91
Frequentist evaluation of group sequential clinical trial designs
Emerson, S. S., Kittelson, J. M., & Gillen, D. L. (2007) · Statistics in Medicine · doi:10.1002/sim.2901 · Cited by 91
Implementing Adaptive Designs: Logistical and Operational Considerations
Quinlan, J., & Krams, M. (2006) · Drug Information Journal · doi:10.1177/216847900604000409 · Cited by 84
Unbiased Estimation of Selected Treatment Means in Two‐Stage Trials
Bowden, J., & Glimm, E. (2008) · Biometrical Journal · doi:10.1002/bimj.200810442 · Cited by 84
Self-citationEstimation in flexible two stage designs
Brannath, W., König, F., & Bauer, P. (2005) · Statistics in Medicine · doi:10.1002/sim.2258 · Cited by 83
Self-citationAdapting the sample size planning of a phase III trial based on phase II data
Wang, S., Hung, H., & O’Neill, R. T. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.217 · Cited by 70
Multiplicity and flexibility in clinical trials
Brannath, W., König, F., & Bauer, P. (2007) · Pharmaceutical Statistics · doi:10.1002/pst.302 · Cited by 53
Self-citationPosch, M., Maurer, W., & Bretz, F. (2010) · Pharmaceutical Statistics · doi:10.1002/pst.413 · Cited by 52
Self-citationRobust One-Way ANOVA under Possibly Non-Regular Conditions
Babu, G. J., Padmanabhan, A. R., & PURI, M. L. (1999) · Biometrical Journal · doi:10.1002/(sici)1521-4036(199906)41:3<261::aid-bimj261>3.0.co;2-u · Cited by 50
A Brief Review on Software Developments for Group Sequential and Adaptive Designs
Wassmer, G., & Vandemeulebroecke, M. (2006) · Biometrical Journal · doi:10.1002/bimj.200510233 · Cited by 41
Group Sequential and Adaptive Designs – A Review of Basic Concepts and Points of Discussion
Vandemeulebroecke, M. (2008) · Biometrical Journal · doi:10.1002/bimj.200710436 · Cited by 36
Operational challenges in adaptive design implementation
Gallo, P. P. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.221 · Cited by 36
Monitoring Clinical Trials with Multiple Arms
Hellmich, M. (2001) · Biometrics · doi:10.1111/j.0006-341x.2001.00892.x · Cited by 35
Krams, M., Burman, C., Dragalin, V., Gaydos, B. L., Grieve, A. P., Pinheiro, J. C., Maurer, W., & Gallo, P. (2007) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543400701643764 · Cited by 33
An improved method of evaluating drug effect in a multiple dose clinical trial
Shen, L. (2001) · Statistics in Medicine · doi:10.1002/sim.842 · Cited by 30
Data Monitoring in Clinical Trials Using Prediction
Evans, S. R., Li, L., & Wei, L. J. (2007) · Drug Information Journal · doi:10.1177/009286150704100606 · Cited by 28
What should be the role of homogeneity testing in adaptive trials?
Gallo, P. P., & Chuang‐Stein, C. (2008) · Pharmaceutical Statistics · doi:10.1002/pst.342 · Cited by 26
Adaptivity in drug discovery and development
Bretz, F., Branson, M., Burman, C., Chuang‐Stein, C., & Coffey, C. S. (2009) · Drug Development Research · doi:10.1002/ddr.20285 · Cited by 24
Self-citation
Cited by
Adaptive designs in clinical trials: why use them, and how to run and report them
Pallmann, P., Bedding, A. W., Choodari-Oskooei, B., Dimairo, M., Flight, L., Hampson, L. V., Holmes, J., Mander, A. P., Odondi, L., Sydes, M. R., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1017-7 · Cited by 829
Adaptive trial designs: a review of barriers and opportunities
Kairalla, J. A., Coffey, C. S., Thomann, M. A., & Muller, K. E. (2012) · Trials · doi:10.1186/1745-6215-13-145 · Cited by 249
Dimairo, M., Pallmann, P., Wason, J., Todd, S., Jaki, T., Julious, S. A., Mander, A. P., Weir, C. J., Koenig, F., Walton, M. K., et al. (2020) · Trials · doi:10.1186/s13063-020-04334-x · Cited by 58
Metadata
- Authors
- Bretz, F., Koenig, F., Brannath, W., Glimm, E., & Posch, M.
- Venue
- Statistics in Medicine
- Publisher
- Wiley
- Published
- 2009-03-13
- Volume
- 28
- Issue
- 8
- Pages
- 1181-1217
- ISSN
- 0277-6715 (ISSN-L)
- 1097-0258
- OpenAlex
- W2030526274
- Cited by
- 266
- References
- 67
- FWCI
- 16.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.